Vitronectin receptor antagonist pharmaceuticals

Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S001110, C424S001810, C534S007000, C534S014000

Reexamination Certificate

active

07090828

ABSTRACT:
The present invention describes novel compounds of the formula:in-line-formulae description="In-line Formulae" end="lead"?(Q)d-Ln-Ch,in-line-formulae description="In-line Formulae" end="tail"?useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

REFERENCES:
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 4859777 (1989-08-01), Toner
patent: 4988827 (1991-01-01), Bergstein et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5064956 (1991-11-01), Kruper, Jr.
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5281704 (1994-01-01), Love et al.
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5350837 (1994-09-01), Bridger et al.
patent: 5376356 (1994-12-01), Morgan, Jr.
patent: 5382654 (1995-01-01), Lyle et al.
patent: 5395609 (1995-03-01), Stuttle
patent: 5403713 (1995-04-01), Bevilacqua et al.
patent: 5412148 (1995-05-01), Keana
patent: 5417959 (1995-05-01), Wallace
patent: 5520904 (1996-05-01), Nosco et al.
patent: 5556939 (1996-09-01), Flanagan et al.
patent: 5567411 (1996-10-01), Keana et al.
patent: 5650134 (1997-07-01), Albert et al.
patent: 5659013 (1997-08-01), Senger et al.
patent: 5659041 (1997-08-01), Pollak et al.
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5679810 (1997-10-01), Love et al.
patent: 5760191 (1998-06-01), Snow et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5801228 (1998-09-01), Hollister et al.
patent: 5804161 (1998-09-01), Long et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 6040311 (2000-03-01), Duggan et al.
patent: 6051207 (2000-04-01), Klaveness et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6056973 (2000-05-01), Allen et al.
patent: 6143274 (2000-11-01), Tweedle et al.
patent: 6232308 (2001-05-01), Askew
patent: 6558649 (2003-05-01), Cheesman et al.
patent: 6569402 (2003-05-01), Cheesman et al.
patent: 6818201 (2004-11-01), Cheesman et al.
patent: 5 314 694 (1994-07-01), None
patent: 2 113 245 (1988-06-01), None
patent: 2 039 259 (1991-10-01), None
patent: 2 156 620 (1994-10-01), None
patent: 2 232 315 (1997-04-01), None
patent: 04 311 023 (1994-10-01), None
patent: 19 536 781 (1997-03-01), None
patent: 19 536 785 (1997-03-01), None
patent: 19 725 368 (1998-12-01), None
patent: 0 107 734 (1987-07-01), None
patent: 0 359 347 (1990-03-01), None
patent: 0 436 005 (1991-10-01), None
patent: 0 606 683 (1994-07-01), None
patent: 0 727 225 (1996-08-01), None
patent: WO 81/01145 (1981-04-01), None
patent: WO 90/03801 (1981-04-01), None
patent: WO 90/05539 (1990-05-01), None
patent: WO 90/12585 (1990-11-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 91/01144 (1991-02-01), None
patent: WO 91/14460 (1991-10-01), None
patent: WO 91/15244 (1991-10-01), None
patent: WO 92/12729 (1992-08-01), None
patent: WO 92/17215 (1992-10-01), None
patent: WO 92/19646 (1992-11-01), None
patent: WO 93/08174 (1993-04-01), None
patent: WO 93/08210 (1993-04-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 94/11499 (1994-05-01), None
patent: WO 94/22497 (1994-10-01), None
patent: WO 95/25543 (1995-09-01), None
patent: WO 96/00574 (1996-01-01), None
patent: WO 96/00730 (1996-01-01), None
patent: WO 96/01653 (1996-01-01), None
patent: WO 96/31243 (1996-10-01), None
patent: WO 96/41803 (1996-12-01), None
patent: WO 97/08145 (1997-03-01), None
patent: WO 94/05328 (1997-04-01), None
patent: WO 97/16474 (1997-05-01), None
patent: WO 97/18207 (1997-05-01), None
patent: WO 97/23480 (1997-07-01), None
patent: WO 93/23074 (1997-09-01), None
patent: WO 98/14220 (1998-04-01), None
patent: WO 98/16256 (1998-04-01), None
patent: WO 95/18619 (1998-07-01), None
patent: WO 98/47541 (1998-10-01), None
patent: WO 99/05107 (1999-02-01), None
patent: WO 99/06049 (1999-02-01), None
patent: WO 99/13329 (1999-03-01), None
patent: WO 99/40947 (1999-08-01), None
patent: WO 99/59640 (1999-11-01), None
patent: WO 00/35887 (2000-06-01), None
patent: WO 02/0430 (2001-01-01), None
patent: WO 01/97848 (2001-12-01), None
patent: WO 01/97860 (2001-12-01), None
patent: WO 01/98294 (2001-12-01), None
Abstract,Nucl. Med. Proceeding of the 42ndAnnual Meeting, May 1995, 36(5), No. 287, p. 71.
American J. Physiol., 1998, 274, H1516-H1523.
Baker, et al.,Life Sci., 1991, 49, 1583-1591.
Batt, et al.,J. Med. Chem., 2000, 43, 41-58.
Bevilacqua, et al.,Proc. Natl. Acad. Sci., 1986, 84, 9238-9242.
Bioconj. Chem., 1997, 8, 611.
Bousquet, et al.,Radiology, 1988, 166, 693.
Brechbiel, M., et al.,J. Chem. Soc. Perkin Trans., 1992, 1, 1175.
Brechbiel, M., et al.,Bioconjugate Chem., 1991, 2, 187.
Burrows, et al.,Proc. Nat. Acad. Sci. USA, 1993, 90, 8996-9000.
Burrows, F.J., et al.,Cancer Research, 1992, 52, 5954-5962.
Burrows, et al.,J. Controlled Release, Jan. 1994, 28(1), 195-202.
Cardiovascular Res., 1997, 36, 408-428.
Cheresh, et al.,Science, 1995, 270, 1500-1502.
Circulation, 1999, 100, 1-275.
Clauss, et al.,J. Biological Chem., 1990, 265(12), 7078-7083.
Clin. Can. Res., 1995, 1, 1623-1634.
Current Pharm. Design, 1997, 3, 545-584.
DDT, 1997, 2, 187-199.
DeGrado, et al.,J. Org. Chem., 1980, 45, 1295.
DeNardo, et al.,Cancer Biotherapy&Radiopharm., Feb. 2000, 15(1), 71-79.
Denekamp, J., et al.,Br. J. Cancer, 1982, 45, 136-139.
Denekamp, J., et al.,Br. J. Cancer, 1982, 46, 711-720.
Denekamp, J.,Acta Radiologica Oncology, 1984,23 Fasc.(4), 217-225.
Denekamp, J.,Cancer Meta. Rev., 1990, 9, 267-282.
Deshpande, S., et al.,J. Nucl. Med., 1990, 31, 473.
DiZio, et al.,Bioconjugate Chem., 1991, 2, 353-366.
Drugs, 1999, 58, 391-396.
Dvorak, et al.,Cancer Cells, 1991, 3, 77-85.
Folkman, J.,Nature Med., 1995, 1, 27-31.
Ghose, et al.,Meth. Enzymology, 1983, 93, 280-333.
Hagemeier, H., et al.,Int. J. Cancer, 1986, 38, 481-488.
Haubner,V313 Nuclear-Medizin, Mar. 1997.
Henry, T., et al.,J. Amer. College Cardiology, 1998, 31, p. 65A.
Horton, et al.,Int. J. Biochem. Cell. Biol., May 1997, 29(5), 721-725.
Hu, et al.,Oncology Res., 1994, 6(7), 321-327.
J. Nucl. Cardiol., 1998, 5, 167-183.
Kennel, et al.,Nuclear Med.&Biol., 1998, 25, 241-246.
Kerr, et al.,Anticancer Res., Mar.-Apr. 1999, 19(2A), 958-968.
Kirk, K.L., et al.,J. Org. Chem., 1978, 43, 4381.
Krenning, et al.,Eur. J. Nucl. Med., 1993, 20, 716-731.
Kreening, et al.,Digestion, 1996, 57, 57-61.
Liu, et al.,Inorg. Chem., 1999, 38(6), 1326-1335.
Margerstadt, et al.,Magn. Reason. Med., 1986, 3, 808.
McDowell, R.S., et al.,J. Amer. Chem. Soc., 1994, 116, 5077-5083.
McNulty, et al.,J. Am. Physiol., 1996, H2283-H2289.
Molema, et al.,Biochemical Pharm., 1998, 55, 1939-1945.
Mueller, et al.,Proc. Natl. Acad. Sci. USA, 1992, 89, 11832-11836.
Olson, et al.,Int. J. Cancer, 1997, 73, 865-870.
O'Reilly, et al.,Cell, 1994, 79, 315-328.
O'Reilly, et al.,Cell, 1997, 88, 277-285.
Orlando, et al.,J. Biological Chem., Oct. 1991, 266(29), 19543-19550.
Remington's Pharmaceutical Sciences, 17thEd.,Mack Publishing Co., Easton, PA, 1985, p. 1418.
Runge, et al.,Radiology, 1988, 166, 835.
Schaper, W., et al., “Collateral circulation: heart, brain, kidney, limbs, kluwer,”Academic Pub., Boston, 1993.
Sellke, et al.,Drugs, 1999, 58(3), 391-396.
S

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Vitronectin receptor antagonist pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vitronectin receptor antagonist pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitronectin receptor antagonist pharmaceuticals will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3714950

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.